InsiderPulse
Dashboard

IDXX

IDEXX Laboratories, Inc.

Health CareS&P 500NASDAQ 100

IDEXX Laboratories, Inc. insider trading

IDEXX Laboratories, Inc. files with the SEC as a In Vitro & In Vivo Diagnostic Substances company headquartered in Westbrook, ME. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent IDXX insider transactions

5 insiders traded IDXX on the open market between Feb 17, 2026 and Sep 04, 2026 — 24 sales worth $23.7M.

Bought
—
Sold
$23.7M

none on a 10b5-1 plan

Net
−$23.7M
Insiders
5

Open-market purchases (code P) and sales (code S) from IDEXX Laboratories, Inc.'s own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 21, 2026. The live dashboard shows new filings the moment they clear.

Every IDXX Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

IDXX insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 9 insiders traded IDXX on the open market: 0 purchases and 64 sales worth $80.4M. In the last four quarters alone: 0 purchases and 56 sales ($70.8M), by 8 insiders.

QuarterBoughtSold
Q2 2026——
Q1 2026—−$29.9M31 sales
Q4 2025—−$6.6M4 sales
Q3 2025—−$34.3M21 sales
Q2 2025—−$3.2M4 sales
Q1 2025—−$6M2 sales
Q4 2024—−$144.6K1 sale
Q3 2024—−$234.7K1 sale
Largest sale
−$4.6M of IDXX by Fennell George (Executive Vice President) on Feb 10, 2025.

Open-market transactions through Jun 30, 2026most recent first

  • Hunt Nimrata

    Executive Vice President

    −$1.1M

    Mar 03, 2026

    1,758 sh · $634.57

  • Mazelsky Jonathan Jay

    President and CEO · Director

    −$2.4M

    Feb 26, 2026

    3,660 sh · $658.92

  • Mazelsky Jonathan Jay

    President and CEO · Director

    −$1.9M

    Feb 26, 2026

    2,859 sh · $659.75

  • Mazelsky Jonathan Jay

    President and CEO · Director

    −$1.9M

    Feb 26, 2026

    2,860 sh · $657.84

  • Hunt Nimrata

    Executive Vice President

    −$1.8M

    Feb 26, 2026

    2,693 sh · $661.54

  • Mazelsky Jonathan Jay

    President and CEO · Director

    −$1.7M

    Feb 26, 2026

    2,589 sh · $663.04

  • Mazelsky Jonathan Jay

    President and CEO · Director

    −$1.1M

    Feb 26, 2026

    1,669 sh · $652.49

  • Mazelsky Jonathan Jay

    President and CEO · Director

    −$882.2K

    Feb 26, 2026

    1,343 sh · $656.85

  • Mazelsky Jonathan Jay

    President and CEO · Director

    −$793.3K

    Feb 26, 2026

    1,200 sh · $661.10

  • Mazelsky Jonathan Jay

    President and CEO · Director

    −$765.5K

    Feb 26, 2026

    1,171 sh · $653.68

  • Mazelsky Jonathan Jay

    President and CEO · Director

    −$727.3K

    Feb 26, 2026

    1,111 sh · $654.63

  • Mazelsky Jonathan Jay

    President and CEO · Director

    −$713.4K

    Feb 26, 2026

    1,095 sh · $651.49

  • Mazelsky Jonathan Jay

    President and CEO · Director

    −$662.2K

    Feb 26, 2026

    1,000 sh · $662.16

  • Erickson Michael G

    Executive Vice President

    −$1.7M

    Feb 17, 2026

    2,694 sh · $628.22

  • Erickson Michael G

    Executive Vice President

    −$806.6K

    Feb 17, 2026

    1,288 sh · $626.26

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

IDEXX Laboratories, Inc. company record

SEC industry classification
In Vitro & In Vivo Diagnostic Substances
Headquarters
Westbrook, ME
Incorporated in
DE
Listed on
Nasdaq
SEC Central Index Key
0000874716

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought IDXX

What the stock actually did in the 90 days following each open-market purchase

Don't check IDXX — let it ping you

Get told the moment an insider moves on IDXX

Pro watches IDEXX Laboratories, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add IDXX to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track IDXX on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read IDXX insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

IQVAWSTRMDDXCMALGNEWBAXZBHHOLXVTRSMCK
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are IDXX insiders buying or selling?
Between Feb 17, 2026 and Sep 04, 2026, 5 IDEXX Laboratories, Inc. insiders made no open-market purchases and 24 sales worth $23.7M, a net sale of $23.7M.
How much IDXX stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 9 IDEXX Laboratories, Inc. insiders made no open-market purchases and 64 sales worth $80.4M. In the four quarters to Jun 30, 2026: no purchases and 56 sales ($70.8M). The largest sale was Fennell George selling $4.6M on Feb 10, 2025.
What was the largest recent IDXX insider trade?
Mazelsky Jonathan Jay (President and CEO · Director) sold $2.4M of IDXX stock on Feb 26, 2026 at about $658.92 a share.
When did an insider last buy IDXX shares?
No open-market purchase by a IDEXX Laboratories, Inc. insider appears in the filings from Feb 17, 2026 to Sep 04, 2026 — every recorded open-market transaction in that period was a sale.
Where does IDXX insider trading data come from?
From the Form 4 filings IDEXX Laboratories, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.